Imperial College London
Portrait Picture

Dr. David James PINATO

Faculty of Medicine, Department of Surgery & Cancer

Clinical Reader in Medical Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2799david.pinato Website

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Pinato:2020:10.1097/CJI.0000000000000295,
author = {Pinato, DJ and Urus, H and Newsom-Davis, T and Du, Parcq P and Belessiotis, K and Mapara, L and Gupta, N and Power, D and Weir, J and Wong, CN and Ratnakumaran, RP and Dominy, K and Khorashad, J and Bower, M},
doi = {10.1097/CJI.0000000000000295},
journal = {Journal of Immunotherapy},
pages = {53--56},
title = {Applicability of routine targeted next-generation sequencing to estimate Tumor Mutational Burden (TMB) in patients treated with immune checkpoint inhibitor therapy.},
url = {http://dx.doi.org/10.1097/CJI.0000000000000295},
volume = {43},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - It remains unclear whether targeted next-generation sequencing (tNGS) conveys a reliable estimate of tumor mutational burden (TMB). We sequenced 79 archival samples of immune checkpoint inhibitors (ICPIs) recipients (57% lung cancer, 43% melanoma) using Ion Ampliseq Cancer Hotspot Panel. Employing multiple cutoff values, we verified that TMB by tNGS did not correlate with response or survival following ICPI. We found enrichment of ATM mutations in ICPI-refractory tumors (P=0.01) to correlate with worse survival (4.2 vs. 10 mo, P=0.03). Limited-coverage tNGS delivers an imprecise estimate of patients' TMB but may aid identification of candidate somatic variants of predictive/prognostic significance.
AU  - Pinato,DJ
AU  - Urus,H
AU  - Newsom-Davis,T
AU  - Du,Parcq P
AU  - Belessiotis,K
AU  - Mapara,L
AU  - Gupta,N
AU  - Power,D
AU  - Weir,J
AU  - Wong,CN
AU  - Ratnakumaran,RP
AU  - Dominy,K
AU  - Khorashad,J
AU  - Bower,M
DO  - 10.1097/CJI.0000000000000295
EP  - 56
PY  - 2020///
SN  - 1524-9557
SP  - 53
TI  - Applicability of routine targeted next-generation sequencing to estimate Tumor Mutational Burden (TMB) in patients treated with immune checkpoint inhibitor therapy.
T2  - Journal of Immunotherapy
UR  - http://dx.doi.org/10.1097/CJI.0000000000000295
UR  - https://www.ncbi.nlm.nih.gov/pubmed/31567705
UR  - https://journals.lww.com/immunotherapy-journal/FullText/2020/02000/Applicability_of_Routine_Targeted_Next_generation.3.aspx
UR  - http://hdl.handle.net/10044/1/74232
VL  - 43
ER  -
Download